GW&K Investment Management LLC Reduces Stock Holdings in Vericel Co. (NASDAQ:VCEL)

GW&K Investment Management LLC decreased its position in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 3.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,323,306 shares of the biotechnology company's stock after selling 46,128 shares during the quarter. GW&K Investment Management LLC owned about 2.77% of Vericel worth $47,122,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of VCEL. PNC Financial Services Group Inc. increased its holdings in shares of Vericel by 8.1% in the third quarter. PNC Financial Services Group Inc. now owns 4,582 shares of the biotechnology company's stock worth $154,000 after acquiring an additional 344 shares in the last quarter. Gotham Asset Management LLC lifted its stake in Vericel by 3.6% in the third quarter. Gotham Asset Management LLC now owns 15,311 shares of the biotechnology company's stock valued at $513,000 after buying an additional 538 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of Vericel by 4.9% in the third quarter. Teacher Retirement System of Texas now owns 12,823 shares of the biotechnology company's stock valued at $430,000 after buying an additional 599 shares during the period. Rhumbline Advisers increased its position in shares of Vericel by 0.5% during the third quarter. Rhumbline Advisers now owns 145,224 shares of the biotechnology company's stock worth $4,868,000 after acquiring an additional 705 shares in the last quarter. Finally, Trexquant Investment LP lifted its position in Vericel by 1.8% in the 4th quarter. Trexquant Investment LP now owns 43,882 shares of the biotechnology company's stock valued at $1,563,000 after acquiring an additional 763 shares in the last quarter.

Vericel Stock Up 0.8 %

Shares of NASDAQ:VCEL traded up $0.40 during midday trading on Tuesday, hitting $51.53. The stock had a trading volume of 418,109 shares, compared to its average volume of 510,174. The company has a market cap of $2.50 billion, a P/E ratio of -5,154.85 and a beta of 1.74. Vericel Co. has a 12 month low of $30.18 and a 12 month high of $53.05. The business's 50-day simple moving average is $47.86 and its 200-day simple moving average is $42.46.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. The company had revenue of $51.28 million during the quarter, compared to the consensus estimate of $49.07 million. Vericel had a net margin of 0.22% and a return on equity of 0.21%. The company's quarterly revenue was up 25.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.16) EPS. As a group, equities analysts predict that Vericel Co. will post 0.1 earnings per share for the current year.

Wall Street Analyst Weigh In

VCEL has been the subject of several recent research reports. StockNews.com raised Vericel from a "sell" rating to a "hold" rating in a research report on Saturday. Truist Financial reiterated a "buy" rating and issued a $54.00 price objective on shares of Vericel in a report on Tuesday, March 26th. HC Wainwright increased their target price on shares of Vericel from $53.00 to $55.00 and gave the stock a "buy" rating in a report on Thursday, May 9th. Finally, TheStreet upgraded shares of Vericel from a "d+" rating to a "c-" rating in a research note on Monday, January 29th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Vericel presently has a consensus rating of "Moderate Buy" and an average target price of $46.80.

Insider Buying and Selling

In other news, CEO Dominick Colangelo sold 17,500 shares of the firm's stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $44.59, for a total value of $780,325.00. Following the completion of the sale, the chief executive officer now directly owns 195,307 shares of the company's stock, valued at $8,708,739.13. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Dominick Colangelo sold 17,500 shares of the firm's stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $44.59, for a total transaction of $780,325.00. Following the completion of the sale, the chief executive officer now owns 195,307 shares in the company, valued at approximately $8,708,739.13. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Robert L. Md Zerbe sold 3,278 shares of the company's stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $51.57, for a total transaction of $169,046.46. Following the completion of the transaction, the director now owns 23,395 shares in the company, valued at approximately $1,206,480.15. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 54,267 shares of company stock worth $2,450,996. Company insiders own 7.20% of the company's stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.